Excellent
Fully Aligned
Patient Risk:
Low
Summary
AI claim aligns with the provided FDA labeling excerpts for alprazolam XR regarding concomitant opioid risks (profound sedation/respiratory depression/coma/death), abuse/misuse/addiction outcomes, and dependence/withdrawal reactions including life-threatening seizures, with label-consistent mitigation (lowest effective dose/minimum duration, close monitoring, and gradual taper).
Category Scores
Accurate Statements
Concomitant use of benzodiazepines (including alprazolam XR) with opioids may result in profound sedation, respiratory depression, coma, and death.
Label sections 5.1 and 7.1 (Opioids) in the provided text.
Abuse, misuse, and addiction with alprazolam XR can lead to serious adverse outcomes including overdose or death, and abuse/misuse often involves doses beyond recommended and/or concomitant use with other medications/alcohol/illicit substances associated with respiratory depression/overdose/death.
Label sections 5.2 and 9.2 in the provided text.
Continued use can lead to physical dependence; abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions that can be life-threatening, including seizures; gradual tapering reduces withdrawal risk.
Label sections 5.3, 2.2 (taper guidance), and 9.3 in the provided text.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No unsafe or contradictory claims were identified relative to the provided labeling excerpts; the AI response tracks the label’s described risks and mitigation language for opioids, abuse/misuse/addiction, and dependence/withdrawal.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement